RxDoctor Payments Data

Laura Shepherd

Family · Minnetonka, MNNPI 1457839342

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 783 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,550 and has fallen 82.0% since, to $820 in 2024. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,251in general payments, 2019–2025

Across 783 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Livanova USA, Inc.$760
  • Lilly USA, LLC$698
  • Neurelis, Inc.$695
  • Amgen$657
  • plus $8K from 44 others

What the payments were for

  • Travel & lodging$4223%
  • Food & beverage$12,64295%
  • Education$1111%
  • Gifts$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,251 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.

See all family providers in Minnesota

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5030$96,768
UbrelvyUbrogepant40$61,831
Emgality PenGalcanezumab-Gnlm56$40,596
NeuproRotigotine29$23,881
Aimovig AutoinjectorErenumab-Aooe26$21,783
Ajovy AutoinjectorFremanezumab-Vfrm22$15,633
QuliptaAtogepant11$11,526
Duloxetine Hcl87$4,746
Pyridostigmine Bromide13$2,141
Carbamazepine ErCarbamazepine18$1,476
Lamotrigine14$1,426
Memantine Hcl39$1,222
Donepezil Hcl64$1,110
Amitriptyline Hcl58$981
Topiramate47$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,596$73,35751 claims
UCB, Inc.Neupro$1,122$23,88129 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$77$2,14113 claims
Upsher-smith Laboratories LLCTopiramate$77$96447 claims
Almatica Pharma LLCSertraline Hcl$51$8521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,121 family providers in Minnesota.

Other family in Minnetonka

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →